Irlanda - inglés - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

Irlanda - inglés - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - cisplatin - concentrate for solution for infusion - 1 milligram(s)/millilitre - platinum compounds; cisplatin

Estados Unidos - inglés - NLM (National Library of Medicine)

west-ward pharmaceuticals corp - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin injection and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existi

Bélgica - inglés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cisplatin 10 mg/10 ml - concentrate for solution for infusion - 1 mg/ml - cisplatin 1 mg/ml - cisplatin

Bélgica - inglés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cisplatin 10 mg/10 ml - concentrate for solution for infusion - 1 mg/ml - cisplatin 1 mg/ml - cisplatin

Bélgica - inglés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cisplatin 10 mg/10 ml - concentrate for solution for infusion - 1 mg/ml - cisplatin 1 mg/ml - cisplatin

Bélgica - inglés - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - cisplatin 10 mg/10 ml - concentrate for solution for infusion - 1 mg/ml - cisplatin 1 mg/ml - cisplatin

Estados Unidos - inglés - NLM (National Library of Medicine)

sagent pharmaceuticals - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin injection is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radio therapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of cisplatin and cyclophosphamide. cisplatin injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received cisplatin injection therapy. cisplatin injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. cisplatin is contraindicated in patients with pre-existing renal impairment. cisplatin should not be employed in myelosuppressed patients, or in patients with hearing impairment. cisplatin is contraindicated in patients with a history of allergic reactions to cisplatin or other platinum containing compounds.

Canadá - inglés - Health Canada

gahler enterprises ltd. - gamma-linolenic acid; cis-linoleic acid; vitamin e - capsule - 100mg; 720mg; 30unit - gamma-linolenic acid 100mg; cis-linoleic acid 720mg; vitamin e 30unit - vitamin e

Australia - inglés - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - cisplatin, quantity: 1 mg/ml - injection, concentrated - excipient ingredients: sodium chloride; sodium hydroxide; water for injections; mannitol; hydrochloric acid - cisplatin is used in the treatment of certain types of cancer, for example ovarian cancer, testicular cancer, bladder cancer and head and neck cancer. cisplatin may be used in combination with other anti-cancer medicines.